Chugai Pharmaceutical Co Ltd ADR (CHGCY)

Currency in USD
20.78
+0.03(+0.14%)
Closed·
Advertisement
Unusual trading volume
CHGCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.4421.79
52 wk Range
20.0034.84
Key Statistics
Prev. Close
20.78
Open
21.79
Day's Range
20.44-21.79
52 wk Range
20-34.84
Volume
907.76K
Average Volume (3m)
248.85K
1-Year Change
-9.218%
Book Value / Share
7.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CHGCY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Earnings

Latest Release
24/07/2026
EPS / Forecast
70.69 / --
Revenue / Forecast
341.58B / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 286.42%
Dividend Yield
-
Industry Median 2.30%
Annualised payout
-
5-Years Growth
-
Growth Streak

Compare CHGCY to Peers and Sector

Metrics to compare
CHGCY
Peers
Sector
Relationship
P/E Ratio
22.7x19.6x−0.4x
PEG Ratio
1.160.030.00
Price/Book
5.3x1.5x2.6x
Price / LTM Sales
8.0x2.2x3.0x
Upside (Analyst Target)
-15.0%56.0%
Fair Value Upside
Unlock12.9%8.7%Unlock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has a collaboration with Phylo, Inc. to deploy an agentic AI platform for biomedical research across its drug discovery workflow. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

Employees
5104

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
302.17M18.37%6.27B
Other Institutional Investors
1.04B63.27%21.60B
Public Companies & Retail Investors
302.11M18.36%6.27B
Total
1.65B100.00%34.14B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Roche Holding AG61.12%1,005,670,00020,867,653
Nomura Asset Management Co., Ltd.3.03%49,899,7001,035,419

FAQ

What Is the Chugai Pharma ADR (OTC Markets: CHGCY) Share Price Today?

The Chugai Pharma ADR stock price today is 20.78 USD.

What Stock Exchange Does Chugai Pharma ADR (CHGCY) Trade On?

Chugai Pharma ADR is listed and trades on the OTC Markets.

What Is the Ticker (Stock Symbol) for Chugai Pharma ADR?

The stock symbol (also called a 'ticker') for Chugai Pharma ADR is "CHGCY."

What Is the Current Chugai Pharma ADR Market Capitalisation?

As of today, Chugai Pharma ADR (OTC Markets: CHGCY) market cap is 68.95B USD.

What Is Chugai Pharma ADR's (CHGCY) Earnings Per Share (TTM)?

The Chugai Pharma ADR EPS is currently 286.42 (Trailing Twelve Months).

Is CHGCY a Buy or Sell From a Technical Analyst Perspective?

Based on today's Chugai Pharma ADR moving averages and other technical indicators, the daily buy/sell signal for CHGCY stock is Strong Sell.

How Many Times Has Chugai Pharma ADR Stock Split?

Chugai Pharma ADR has split 1 times. (See the CHGCY stock split history page for full effective split date and price information.)

How Many Employees Does Chugai Pharma ADR Have?

Chugai Pharma ADR has 5104 employees, based on their latest Companies House report.

What is the current trading status of Chugai Pharma ADR (OTC Markets: CHGCY)?

As of 16/09/2026, Chugai Pharma ADR (CHGCY) is trading at a share price of 20.78 USD, with a previous close of 20.78 USD. The stock has fluctuated within a day range of 20.44 USD to 21.79 USD, while its 52-week range spans from 20.00 USD to 34.84 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.